Antibody

1,020개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,020 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Platinum-SensitiveLungSmallCellC+1
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ])

Lymphoma, Follicular · Lymphoma, Follicular

#LymphomaFollicular#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

adjuvant (Atezolizumab, Atezolizumab (adjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

neoadjuvant (Atezolizumab, Atezolizumab (neoadjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + Ipatasertib)

Gastric Adenocarcinoma; Metastatic Gastric Cancer · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#monoclonal-antibody#MetastaticGastricCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + RP1)

Triple Negative Breast Neoplasms · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab, 6-mercaptopurine, 6-thioguanine)

Solid Tumor, Adult; Metastatic Cancer · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#monoclonal-antibody#SolidTumor+3
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Bevacizumab, RHUMAB VEGF (Avastin, Avastin (Bevacizumab, RHUMAB VEGF))

Rectal Cancer · Rectal Cancer

#RectalCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 1

bevacizumab, reference product (Avastin®, Avastin® (bevacizumab, reference product))

Metastatic Colorectal Cancer (mCRC) · Metastatic Colorectal Cancer (mCRC)

#MetastaticColorectalCancermCRC#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSyndax PharmaceuticalsPhase 1

Axatilimab (Axatilimab)

Solid Tumor; Metastatic Tumor · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#MetastaticTumor+1
Trials 1Status Active
AntibodyLimited DatastaleSamsung Medical CenterPhase 2

durvalumab (Imfinzi, BAVC-C+Durvalumab)

Cervical Cancer · Cervical Cancer

#CervicalCancer#Antibody#Phase2#monoclonal-antibody#Samsung
Trials 1Status Active
AntibodyLimited DatastaleNavire Pharma Inc., a BridgeBio…Phase 1

nivolumab (Opdivo, BBP-398 with nivolumab)

Non Small Cell Lung Cancer; Solid Tumor · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastaleAmgenPhase 2

Blinatumomab (BLINCYTO, BLINCYTO (Blinatumomab))

Mixed Phenotype Acute Leukemia (MPAL); Measurable Residual Disease (MRD) · Mixed Phenotype Acute Leukemia (MPAL)

#MixedPhenotypeAcuteLeukemiaMPAL#Antibody#Phase2#monoclonal-antibody#MeasurableResidualDiseaseMRD+1
Trials 1Status Active
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

Nivolumab (BMS-936558, BMS-936558 (Nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Active
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Melanoma (Skin) · Melanoma (Skin)

#MelanomaSkin#Antibody#Phase2#monoclonal-antibody#MD
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleHighlight TherapeuticsPhase 2

pembrolizumab (Keytruda, BO-112 with pembrolizumab)

Colorectal Cancer; Gastric Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#GastricCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleBioXcel Therapeutics IncPhase 2

pembrolizumab (Keytruda, BXCL701 plus Pembrolizumab)

Prostate Cancer; Neuroendocrine Tumors · Prostate Cancer

#ProstateCancer#Antibody#Phase2#monoclonal-antibody#NeuroendocrineTumors+1
Trials 1Status Active
AntibodyLimited DatastaleByondis B.V.Phase 1

pembrolizumab (Keytruda, BYON4228 + Pembrolizumab)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#Byondis
Trials 1Status Recruiting

19 / 51 pages

← PreviousNext →